<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019509</url>
  </required_header>
  <id_info>
    <org_study_id>TgABstudy Brussels</org_study_id>
    <nct_id>NCT04019509</nct_id>
  </id_info>
  <brief_title>The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology</brief_title>
  <acronym>TgAB</acronym>
  <official_title>The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The influence of thyroid autoantibodies on thyroid function in pregnancy after fertility
      treatment is not well known.

      The objectives of the present study are:

        1. To monitor the course of thyroid function during pregnancy and to compare between women
           with and without thyroid autoantibodies.

        2. Compare pregnancy outcome between women with and without thyroid antibodies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid autoantibodies and / or abnormal thyroid function are associated with fertility
      problems.

      A possible explanation for this is, an influence of thyroid autoantibodies on the functioning
      of the thyroid gland. It is therefore recommended to check thyroid gland function and for the
      presence of autoantibodies before pregnancy. In general, 2 types of thyroid autoantibodies
      are known: anti-thyreoperoxidase autoantibodies and anti-thyroglobulin autoantibodies.

      In case of abnormal thyroid function, treatment is sometimes necessary in regards to
      fertility. The risk of abnormal thyroid function is increased in women with thyroid
      autoantibodies during pregnancy. Therefore, thyroid function is regularly monitored during
      pregnancy in women with thyroid antibodies. The influence of thyroid autoantibodies on
      thyroid function in pregnancy after fertility treatment is not well known.

      The objectives of the present study are:

        1. To monitor the course of thyroid function during pregnancy and to compare between women
           with and without thyroid autoantibodies.

        2. Compare pregnancy outcome between women with and without thyroid antibodies
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thyroid fonction</measure>
    <time_frame>12 months</time_frame>
    <description>TSH, FT4 evolution during pregnancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative delivery rate</measure>
    <time_frame>12 months</time_frame>
    <description>live birth delivery after IVF stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative pregnancy rate</measure>
    <time_frame>12 months</time_frame>
    <description>pregnancy rate after IVF stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>12 months</time_frame>
    <description>miscarriage rate after IVF stimulation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Fertility Disorders</condition>
  <condition>Thyroid Dysfunction</condition>
  <arm_group>
    <arm_group_label>Tg AB positive, TPO AB negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tg AB negative, TPO AB negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Includes patients without thyroid autoantibodies at start of fertility treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tg AB positive, TPO AB positive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>blood test for thyroid antibodies and thyroid function (TSH, FT4)</description>
    <arm_group_label>Tg AB negative, TPO AB negative</arm_group_label>
    <arm_group_label>Tg AB positive, TPO AB negative</arm_group_label>
    <arm_group_label>Tg AB positive, TPO AB positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follow up treatment outcome</intervention_name>
    <description>questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery</description>
    <arm_group_label>Tg AB negative, TPO AB negative</arm_group_label>
    <arm_group_label>Tg AB positive, TPO AB negative</arm_group_label>
    <arm_group_label>Tg AB positive, TPO AB positive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first cycle of assisted reproductive technology with follow up of thyroid function at
             the Universitair Ziekenhuis Brussel

          -  age &gt;= 18 and &lt;= 36 years

          -  body mass index between 18 and 35

        Exclusion Criteria:

          -  Patients with clinical thyroid dysfunction

          -  Patients being treated with levothyroxine or antithyroid drugs

          -  Patients being treated with glucocorticosteroids

          -  Patients undergoing in vitro maturation or preimplantation genetic testing.

          -  Poor responders during IVF/ICSI stimulation, using the Bologna criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>valerie uvin, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussels</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>valerie uvin, md</last_name>
    <phone>486073292</phone>
    <phone_ext>0032</phone_ext>
    <email>valerieuvin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>david unuane, md phd</last_name>
    <phone>024774671</phone>
    <phone_ext>0032</phone_ext>
    <email>david.unuane@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>valerie uvin, md</last_name>
      <phone>486073292</phone>
      <phone_ext>0032</phone_ext>
      <email>valerieuvin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>david unuane, md phd</last_name>
      <phone>24774671</phone>
      <phone_ext>0032</phone_ext>
      <email>david.unuane@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Valerie Uvin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

